- Home
- IRMD vs OCS Comparison
IRMD vs OCS Comparison
Compare IRMD & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRMD | OCS |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | IRMD | OCS |
|---|---|---|
| Price | $97.44 | $20.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $72.00 | $39.57 |
| AVG Volume (30 Days) | 78.2K | ★ 106.1K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $80,511,268.00 | $991,999.00 |
| Revenue This Year | $15.17 | $14.53 |
| Revenue Next Year | $10.15 | $691.13 |
| P/E Ratio | $58.96 | ★ N/A |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $47.48 | $14.00 |
| 52 Week High | $98.53 | $23.08 |
Technical Indicators
Market Signals| Indicator | IRMD | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 49.26 |
| Support Level | $90.92 | $20.18 |
| Resistance Level | $98.53 | $21.11 |
| Average True Range (ATR) | 2.27 | 0.72 |
| MACD | -0.41 | -0.06 |
| Stochastic Oscillator | 85.81 | 39.59 |
Price Performance
Historical ComparisonAbout IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.